{"id":"W4389519919","doi":"10.1038/s41591-023-02726-5","title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; McGill University; Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche; Roche","keywords":"Refractory (planetary science); Internal medicine; Lymphoma; Medicine; Oncology; Aggressive lymphoma; Brentuximab vedotin; Cancer research; Biology; Hodgkin lymphoma; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001264424,0.0005068909,0.001176005,0.001225314,0.0001303685,0.00001787408,0.0003630578,0.000861903,0.003050366],"category_scores_gemma":[0.001915988,0.0003115066,0.0001370165,0.003277071,0.0003014199,0.0000896042,0.0001130757,0.002313262,0.000157438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000756387,"about_ca_system_score_gemma":0.001227151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001513896,"about_ca_topic_score_gemma":0.0002704076,"domain_scores_codex":[0.9951923,0.000266072,0.0007107452,0.0008719165,0.001861446,0.001097551],"domain_scores_gemma":[0.9970591,0.0007954191,0.0003530981,0.0009923475,0.0002963023,0.0005037404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7383732,0.01084207,0.0005297054,0.0007065208,0.0003927388,0.03208627,0.006481243,0.000004313286,0.07579387,0.0001154201,0.08092721,0.0537474],"study_design_scores_gemma":[0.8027437,0.01964016,0.001064318,0.001462109,0.000201306,0.0003408369,0.001854246,0.0008539819,0.00542948,0.00005652516,0.1659094,0.0004439525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9786819,0.005331939,0.0000107196,0.003854004,0.001008861,0.00243464,0.000036355,0.0003279772,0.008313601],"genre_scores_gemma":[0.9582708,0.0008093536,0.0001008022,0.001380127,0.002128478,0.0001625051,0.0004166846,0.0001558302,0.03657541],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08498221,"threshold_uncertainty_score":0.9999884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02209722025973871,"score_gpt":0.3634544553876059,"score_spread":0.3413572351278672,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}